RT Journal Article
T1 An optimized MNK1b aptamer, apMNKQ2, and its potential use as a therapeutic agent in breast cancer
A1 Pinto Díez, C.
A1 Ferreras Martín, R.
A1 Carrión Marchante, R.
A1 Klett Mingo, J.I.
A1 García Hernández, M.
A1 Pérez Morgado, M.I.
A1 Sacristán, S.
A1 Barragán, M.
A1 Seijo Vila, Marta
A1 Tundidor, Isabel
A1 Blasco Benito, Sandra
A1 Pérez Gómez, Eduardo
A1 Gómez Pinto, I.
A1 Sánchez García, María Cristina
A1 González, C.
A1 González, V.M.
A1 Martín, M.E.
AB Breast cancer is the most commonly diagnosed and leading cause of cancer death among women worldwide. Mitogen-activated protein kinase-interacting kinases (MNKs) promote the expression of several oncogenic proteins and are overexpressed in several types of cancer. In human cells, there are four isoforms of MNKs. The truncated isoform MNK1b, first described in our laboratory, has a higher basal activity and is constitutively active. Aptamers are emerging in recent years as potential therapeutic agents that show significant advantages over drugs of other nature. We have previously obtained and characterized a highly specific aptamer against MNK1b, named apMNK2F, with a dissociation constant in the nanomolar range, which produces significant inhibition of proliferation, migration, and colony formation in breast cancer cells. Furthermore, its sequence analysis predicted two G-quadruplex structures. In this work, we show the optimization process of the aptamer to reduce its size, improving its stability. The obtained aptamer, named apMNKQ2, is able to inhibit proliferation, colony formation, migration, and invasion in breast cancer cells. In murine models of breast cancer, apMNKQ2 has demonstrated its efficacy in reducing tumor volume and the number of metastases. In conclusion, apMNKQ2 could be used as an anti-tumor drug in the future.
PB Cell Press
SN 2162-2531
YR 2022
FD 2022-11-14
LK https://hdl.handle.net/20.500.14352/102902
UL https://hdl.handle.net/20.500.14352/102902
LA eng
NO Pinto-Díez C, Ferreras-Martín R, Carrión-Marchante R, Klett-Mingo JI, García-Hernández M, Pérez-Morgado MI, Sacristán S, Barragán M, Seijo-Vila M, Tundidor I, Blasco-Benito S, Pérez-Gómez E, Gómez-Pinto I, Sánchez C, González C, González VM, Martín ME. An optimized MNK1b aptamer, apMNKQ2, and its potential use as a therapeutic agent in breast cancer. Mol Ther Nucleic Acids. 2022 Nov 15;30:553-568. doi: 10.1016/j.omtn.2022.11.009. PMID: 36457699; PMCID: PMC9705393.
NO Ministerio de Economía y Competitividad
NO Ministerio de Ciencia, Innovación y Universidades
NO Ministerio de Ciencia e Innovación (MCIN) / AEI /10.13039/501100011033
NO Comunidad de Madrid
DS Docta Complutense
RD 26 feb 2026